Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection.

Ex vivo study evaluating the effects of Thymosin alpha 1 on blood samples from individuals with post-acute sequelae of SARS-CoV-2 infection.

“Our data obtained from an ex vivo study, showed that in PASC individuals with a chronically altered immune response, Tα1 improve the restoration of an appropriate response”

10 PASC individuals, 15 acute COVID-19 patients, and 5 healthy donors.

“Transcriptional levels in human blood samples from individuals with acute COVID-19 (a-COV, N = 15), PASC (N = 10) and healthy donors (HD, N = 5).”

Blood samples were exposed to Thymosin alpha 1 for 48 hours.

“Blood samples were exposed to 50 μg/ml Tα1 for 48 h at 37° C in 5% CO2 (SciClone, Pharmaceutical).”

Thymosin alpha 1 treatment decreased the expression of pro-inflammatory cytokines IL-6 and IFN-γ and increased the expression of IL-10 in T cell compartments.

“Ex vivo treatment with Tα1 determined a significant decrease in cells expressing IL-6 and IFN-γ in the CD8 + and CD4+ T compartments and a significant increase in cells expressing IL-10”

The study included a limited number of patients.

“A limitation of the study is the limited number of patients included in this cohort.”